Drugs in Dev.
Ophthalmology
Preclinical
Switzerland 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CDR202
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $487.7 million
Deal Type : Collaboration
Details : Under the collaboration, the partners will advance CDR-Life’s preclinical antibody fragment-based therapeutic including CDR202, targeting a key pathway in geographic atrophy (GA).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 02, 2023
Lead Product(s) : CDR202
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $487.7 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of Optogenetics-based AAV gene therapy as the basis of successful therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 21, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $494.0 million
Deal Type : Licensing Agreement
Details : Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $494.0 million
Deal Type : Licensing Agreement
